Leukemia & Lymphoma Society of Canada

2 Lansing Square, Suite 804
Toronto, ON M2J 4P8
President: Shelagh Tippet-Fagyas
Board Chair: Ted Moroz

Website: www.llscanada.org
Charitable Reg. #: 10762 3654 RR0001

Sector: Health - Cancer

Operating Charity

Charity Rating

Subscribe now for charity ratings

Donor Accountability

Grade: B-

The grade is based on the charity's public reporting of the work it does and the results it achieves.

Financial Transparency

Audited financial statements for current and previous years available on the charity's website [ Audited financial statement for most recent year ]

Need for Funding

Funding Reserves Program Costs

Spending Breakdown

Full-time staff #53

Avg. Compensation $81,165

Top 10 Staff Salary Range

$350k +	0
$300k - $350k	0
$250k - $300k	0
$200k - $250k	1
$160k - $200k	1
$120k - $160k	2
$80k - $120k	6
$40k - $80k	0
< $40k	0

Information from most recent CRA Charities Directorate filings for F2016

About Leukemia & Lymphoma Society of Canada:

Founded in 1955, Leukemia & Lymphoma Society of Canada (LLSC) works to find cures for all forms of blood cancer and improve the quality of life of patients and their families. To achieve its mission, LLSC has three main programs: research, patient support, and education. In F2016, research made up 47% of program costs, education made up 36%, and patient support made up 18%.

Leukemia & Lymphoma Society of Canada has established partnerships with various organizations to run its programs, including a long-standing partnership with United Food and Commercial Workers (UFCW). UFCW runs fundraising events to provide funds for LLSC’s research, patient support and educational programs.

Leukemia & Lymphoma Society of Canada’s research programs provide grants for 30 Canadian research projects annually. These projects investigate new treatments and possible cures for blood cancers. The Therapy Acceleration Program (TAP) accounts for a large portion of LLSC research funding. This program funds clinical research projects run by companies that focus on improving the quality of care that blood cancer patients receive. One company that received funding from TAP is Celator Pharmaceuticals. The company is developing a drug called VYXEOS, designed to improve the survival rate of patients living with acute myeloid leukemia (AML). In March 2016, clinical trial results showed that the drug significantly improves the survival rate of AML patients.

Leukemia & Lymphoma Society of Canada’s education programming focuses on educating the public and healthcare professionals on the challenges faced by people affected by leukemia and lymphoma. The charity has an educational video library, webcasts and free information booklets posted online for people to access. It also holds information sessions, health exhibits, professional conferences, and health education training sessions.

The First Connection Program is one of LLSC’s patient services programs. First Connection connects patients at any stage of diagnosis with a volunteer who has gone through the same challenges of living with blood cancer – LLSC’s website states that over 300 volunteer matches are available for patients. The LLSC also runs Family Support Groups that provide patients and their families with a place to share information, support, knowledge and feelings in a friendly environment. There are currently 15 groups stationed across Canada. Other patient services programs include patient education programs as well as one-to-one information and support services to caregivers and patients.

Financial Review:

Leukemia and Lymphoma Society of Canada is a big-cap charity with total donations of $12.5m in F2016. Administrative costs are 14% of revenues and fundraising costs are 32% of donations. Per dollar donated to the charity, $0.54 goes towards its programs and research grants, which falls outside Ci’s reasonable range for overhead spending. The charity’s funding reserves of $7.1m include $350k in donor-endowed funds. Excluding donor-endowed funds, the charity’s reserves can cover annual program costs and grants for just over 1 year.

This charity report is an update that is currently being reviewed by Leukemia and Lymphoma Society of Canada. Comments and edits may be forthcoming.

Updated on July 18, 2017 by Katie Khodawandi.

Financial Ratios Fiscal year ending June	2016	2015	2014
Administrative costs as % of revenues	13.6%	10.0%	9.6%
Fundraising costs as % of donations	32.4%	31.5%	39.6%
Program cost coverage (%)	110.2%	94.2%	71.2%

Summary Financial Statements All figures in $000s	2016	2015	2014
Donations	12,477	13,293	14,309
Investment income	56	265	335
Other income	20	23	25
Total revenues	12,553	13,582	14,669
Program costs	3,655	4,809	5,250
Grants	2,793	2,493	1,929
Administrative costs	1,699	1,327	1,381
Fundraising costs	4,041	4,192	5,669
Cash flow from operations	365	761	441
Funding reserves	7,106	6,875	5,113

Note: The audited financial statements report direct research expenses and allocated research expenses. Direct research expenses are reported as grants expenses and allocated research expenses are included in program costs. The audited financial statements include direct event fundraising costs as a reduction in revenue. Ci has made adjustments to include this cost in fundraising expenses. As a result, both revenues and expenses increased by $788k in F2016, $938k in F2015 and $1.6m in F2014. The audited financial statements report net realized gain on sale of investments as a non-cash item. Ci adjusted remove this figure from investment income, decreasing revenue by $217 in F2016, $14k in F2015 and $25k in F2014. Ci backed out amortization on a pro-rata basis from program, administrative and fundraising costs. Ci did not report unspent investment income, which the charity includes in its endowment fund, as part of donor-endowed funds.

Comments added by the Charity:

Below are comments added by the charity for a past profile. New comments made by the charity for this updated profile may be forthcoming.

The Leukemia & Lymphoma Society of Canada (LLSC) expanded its mission in 2005 to include patient education, support and programs in addition to the research projects that had been funded since our inception in 1955. This effort, which included the addition of Social Workers and/or Oncology Nurses to support patients to our staff team, has gradually spread out across Canada and continues to grow to this present day. At the same time, it was decided that LLSC should increase its geographical reach outside of Vancouver, Calgary and Toronto so we could offer support coast-to-coast. In the last few years, we have added in stages staffed offices in Montreal, Edmonton, Saskatoon, Ottawa, Quebec City and Halifax (as of January, 2011) to meet this mandate. LLSC has also made a concerted effort to provide all materials and programming in both official languages, which were previously only available in English. These projects involve large expenditures up front, but were deemed crucial to our ability to properly meet our mission across Canada. We are proud LLSC is now truly a national organization that can help Canadians coast-to-coast through their journey with blood cancer and also give them hope for a healthy future by funding top-notch research.